TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23218935
Drug: Bupivacaine .5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine .5% with hydromorphone .04 mg/hour
Study: 20824678
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg saxagliptin once daily for 18 weeks
Study: 20824678
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sitagliptin once daily for 18 weeks
Study: 20824678
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg saxagliptin plus metformin
Study: 20824678
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sitagliptin plus metformin
Study: 18410225
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate 1000 mg/day + vitamin D(2) 1000 IU
Study: 18410225
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate 1000 mg/day + placebo
Study: 12724503
Drug: Sertraline (N=70)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (N=70)
Study: 1930344
Drug: Kava extract
Normalized name: Kava extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kava extract WS 1490 (Laitan) 3 x 100 mg/day
Study: 7149056
Drug: Intravenous haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous haloperidol
Study: 31776310
Drug: Mail-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mail-based intervention using the TAKE10! Program (monthly mail with self-check sheets and feedback for 5 months)
Study: 22081481
Drug: saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 5 mg daily
Study: 17403312
Drug: Propofol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (60 ml/min)
Study: 15188109
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of tranexamic acid
Study: 2642497
Drug: Thymosin alpha
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha 1 (900 micrograms/m2 subcutaneously twice weekly for eight doses)
Study: 31568997
Drug: Integrated home-visitation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated home-visitation program delivered by community health workers including psychosocial stimulation and health promotion during bi-weekly home visits over one year.
Study: 21302042
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of enteric-coated pantoprazole
Study: 16186075
Drug: Intranasal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 17beta‐estradiol (Aerodiol) administration
Study: 12519853
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate 3.6 mg by sc injection every 4 weeks for 12 weeks (Group 1)
Study: 12519853
Drug: Goserelin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin plus transdermal testosterone (Androderm 5 mg topically daily) (Group 2)
Study: 12519853
Drug: Goserelin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin plus testosterone plus an aromatase inhibitor (anastrozole 1 mg orally daily) (Group 3)
Study: 10992176
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (2 mg 17beta-estradiol plus 1 mg norethindrone acetate daily)
Study: 1475038
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 0.25 mg rolipram/day
Study: 1475038
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 0.50 mg rolipram/day
Study: 1475038
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 1.00 mg rolipram/day
Study: 28856388
Drug: Polidocanol injections
Normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polidocanol injections
Study: 26598571
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment schedules (specific dosage and duration not mentioned)
Study: 22993930
Drug: Clarithromycin plus
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin plus standard antibacterial therapy (3rd generation cephalosporins)
Study: 22993930
Drug: Standard antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibacterial therapy (3rd generation cephalosporins)
Study: 19915829
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg (nighttime dosing)
Study: 19915829
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg (daytime dosing)
Study: 19915829
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of nighttime vs daytime dosing
Study: 12775860
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 250 micro g administered twice daily
Study: 10684846
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control group: children with strabismus)
Study: 9085945
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg bolus followed by an infusion of 5 mg/h for 24 h
Study: 11981600
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg methadone
Study: 3536377
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg methadone
Study: 3536377
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg methadone
Study: 29231565
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of human placenta tissue fluid combined with oral administration of metformin hydrochloride enteric-coated tablets
Study: 29231565
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of metformin hydrochloride enteric-coated tablets
Study: 22615527
Drug: Oxitropium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium 0.2 mg x 3 mg
Study: 10999066
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg i.v. prior to chemotherapy followed by two further doses of 8 mg i.v. over the first 24 hours, then 8 mg b.d. orally for the next 5 days
Study: 10999066
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg i.v. prior to chemotherapy followed by 2 i.v. doses of 10 mg each, 4 hours apart, then 20 mg orally for the next 5 days
Study: 1649672
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (NOVO)
Study: 3073903
Drug: Monocomponent porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monocomponent porcine insulin
Study: 30292891
Drug: Adjunctive urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive urine LAM testing (n=1257)
Study: 30292891
Drug: Routine diagnostics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine diagnostics plus adjunctive urine LAM testing (n=1257)
Study: 19224163
Drug: Anluohuaxian tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anluohuaxian tablet + gamma-IFN
Study: 19224163
Drug: Anluohuaxian tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anluohuaxian tablet
Study: 19224163
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (anluohuaxian tablet + gamma-IFN)
Study: 17966930
Drug: Conventional cytopathology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cytopathology of oral brush biopsies
Study: 11726432
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B complex (folate 2.5 mg, B(6) 25 mg, and B(12) 500 microg) daily for 1 week before surgery
Study: 8485020
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg MTX i.v.
Study: 8485020
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg MTX i.m.
Study: 8485020
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg MTX p.o.
Study: 8485020
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg MTX (all routes)
Study: 3318348
Drug: Ketotifen 2
Normalized name: ketotifen 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 2 mg/day for 7 days
Study: 31273290
Drug: Low-dose AA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose AA (250 mg)
Study: 30264056
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of amino acid and sodium hyaluronate gel
Study: 30264056
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline solution (Control)
Study: 26866082
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 20 mcg 2-hourly up to a maximum of 4 doses
Study: 26866082
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin according to WHO protocol
Study: 22248659
Drug: Mericitabine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mericitabine (500 or 1000 mg, twice daily) plus danoprevir (100 or 200 mg, every 8 hours, or 600 or 900 mg, twice daily)
Study: 19744259
Drug: Intralesional SSG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional SSG + intramuscular SSG
Study: 19744259
Drug: Intralesional SSG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional SSG + oral ketoconazole
Study: 15713352
Drug: Voglibose (0.4-0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (0.4-0.6 mg/day)
Study: 12798444
Drug: Fluvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (80 mg slow release matrix tablet, acute application)
Study: 12798444
Drug: Fluvastatin (2-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (2-month medication regimen)
Study: 7634730
Drug: Cortisone injection
Normalized name: hydrocortisone Injection
DrugBank: Cortisone (DB14681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone injection with lidocaine
Study: 7634730
Drug: Cortisone injection
Normalized name: hydrocortisone Injection
DrugBank: Cortisone (DB14681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone injection with bupivacaine
Study: 7634730
Drug: Cortisone injection
Normalized name: hydrocortisone Injection
DrugBank: Cortisone (DB14681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone injection (regardless of anesthetic)
Study: 411398
Drug: Aerosolized atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized atropine sulphate (1 mg)
Study: 411398
Drug: Isoproterenol (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (0.625 mg)
Study: 411398
Drug: Isoproterenol or
Normalized name: isoproterenol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol or atropine pre-treatment
Study: 31585191
Drug: SA3Ag vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA3Ag vaccine (low-dose: 102; mid-dose: 101; high-dose: 101)
Study: 31585191
Drug: SA3Ag vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA3Ag vaccine (all doses)
Study: 31585191
Drug: SA3Ag vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA3Ag vaccine (mid-dose and high-dose)
Study: 31585191
Drug: SA3Ag vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA3Ag vaccine (low-dose and placebo)
Study: 28842581
Drug: C34-PEG4-Chol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: C34-PEG4-Chol (10 mg, 10 mg, and 20 mg)
Study: 28842581
Drug: C34-PEG4-Chol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: C34-PEG4-Chol (10 mg, 20 mg)
Study: 25757714
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted CBT for psychosis (CaCBTp) plus treatment as usual (TAU)
Study: 22874661
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise (3 weekly sessions for 12 weeks)
Study: 22874661
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (1 weekly session for 12 weeks)
Study: 19788025
Drug: Desloratadine, 5
Normalized name: Desloratadine, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine, 5 mg daily for 15 days
Study: 8508863
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg zofenopril once daily
Study: 3327854
Drug: Flordipine 25
Normalized name: felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flordipine 25 mg
Study: 3327854
Drug: Flordipine 50
Normalized name: felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flordipine 50 mg
Study: 31279794
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hydrocortisone and 10 mg yohimbine combined
Study: 27785892
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant IL-2
Study: 17362456
Drug: 2% lidocaine-soaked
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine-soaked sponge (Group L, n = 32)
Study: 15465617
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of pegylated interferon weekly alone
Study: 9495509
Drug: Calcium (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1600 mg/day as the citrate)
Study: 7992293
Drug: Lovastatin (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20, 40 and 80 mg/day)
Study: 7992293
Drug: Pravastatin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10, 20 and 40 mg/day)
Study: 1227823
Drug: Betahistidine hydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistidine hydrochloride, 4 mg three times daily
Study: 18492265
Drug: NP 06‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP 06‐1 (370 mg each, two capsules twice daily)
Study: 8614967
Drug: 600 IU
Normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU of rHuEPO per kg of body weight intravenously twice a week
Study: 1393034
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of up to 20 mg papaveretum
Study: 2862523
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of lignocaine and hydrocortisone
Study: 26963505
Drug: Dapivirine vaginal
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine vaginal ring (25 mg), inserted 4-weekly for 12 weeks
Study: 26963505
Drug: Placebo ring,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ring, inserted 4-weekly for 12 weeks
Study: 14871462
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g oral moist snuff
Study: 9137797
Drug: CMF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF treatment in TP-positive tumours
Study: 25523190
Drug: Stoss vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stoss vitamin D therapy
Study: 9174681
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg esuprone
Study: 6367452
Drug: Intravenous cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cimetidine (300 mg every six hours)
Study: 6367452
Drug: Cimetidine tablets
Normalized name: Cimetidine Tablets
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine tablets (300 mg three times a day and at bedtime)
Study: 6367452
Drug: Hourly antacids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly antacids (Mylanta II liquid 30 ml every hour)
Study: 6367452
Drug: Cimetidine plus
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine plus hourly antacids
Study: 30811630
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 2g of nanorap formulation (50mg lidocaine + 50mg prilocaine)
Study: 30811630
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control formulation)
Study: 30811630
Drug: Nanorap formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanorap formulation
Study: 25631504
Drug: Metronidazole sustained-release
Normalized name: metronidazole Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole sustained-release film combined with minocycline hydrochloride
Study: 22775467
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 820 nm; continuous wave; output power: 50 mW; exposure duration: 5 sec; energy dose: 0.25 J; energy density: 7.96 J/cm(2) for each shot
Study: 22775467
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (no laser treatment)
Study: 19879750
Drug: E120 (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: E120 (epirubicin 120 mg/m²)
Study: 19879750
Drug: EC-CMF (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-CMF (epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m² followed by CMF)
Study: 18517036
Drug: Gaboxadol (GBX)
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol (GBX) 15 mg
Study: 16029679
Drug: 5% niacinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% niacinamide applied twice daily for 12 weeks
Study: 16029679
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control applied twice daily for 12 weeks
Study: 385948
Drug: No immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunotherapy
Study: 3312020
Drug: Amoxicillin with
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin with clavulanic acid
Study: 6339961
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (intensive courses of methotrexate with vincristine and prednisone reinductions and administration of cyclophosphamide)
Study: 6339961
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (courses of methotrexate alternated with courses of 6‐mercaptopurine during consolidation and intensification therapy)
Study: 6339961
Drug: Protocol 0276/A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 0276/A (similar to regimen B but with L‐asparaginase and prolonged therapy duration)
Study: 6339961
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methotrexate and 6‐mercaptopurine
Study: 30390895
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day of EPA‐enriched oral nutrition supplementation (ONS)
Study: 20408345
Drug: sublingual latex
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual latex extract
Study: 17223657
Drug: Leflunomide (LEF)
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide (LEF) 20 mg once daily for 24 weeks
Study: 17078441
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (penetrating needling, scalp acupuncture, strong/electric needling on body points)
Study: 15220599
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement (InflammEnz, Enzymes, Inc., Parkville, Mo.) - four capsules per day for 7 days
Study: 10910797
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication follow-up plus a condition designed to control for therapist time and provide environmental changes unrelated to cognitive deficits
Study: 10910797
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication follow-up only
Study: 8835112
Drug: ZVD (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZVD (500 mg daily) + rG‐CSF (10 micrograms/Kg/biweekly) + Epo (50 IU/Kg/biweekly)
Study: 8835112
Drug: ZVD (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZVD (500 mg/day) alone
Study: 1279214
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg terazosin
Study: 2897299
Drug: Atenolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (200 mg)
Study: 28731003
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 intravenously every 3 weeks for three cycles followed by Pemetrexed consolidation every 3 weeks for 4 cycles.
Study: 28731003
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: Standard therapy with Etoposide 50 mg/m2 and Cisplatin 50 mg/m2 intravenously every 4 weeks for two cycles followed by two cycles of consolidation platinum-based doublet chemotherapy.